A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB)

Stem cell experts recognize the potential of exosomes for treating COVID-19 pneumonia, but caution that rigorous clinical testing is needed.

Modifying how embryonic stem cells use sugar can switch them into a totipotent state, A*STAR researchers say.

Just because a molecular target resides inside a cancer cell does not mean that it cannot be targeted by antibodies, says Qi Zeng, founder of A*STAR spin-off company Intra-ImmuSG.

Mutations accelerating the degradation of the protein gelsolin are responsible for amyloid plaque buildup in patients suffering from familial amyloidosis, Finnish type.

A*STAR researchers have figured out the detailed structure of a type of protein filament responsible for tethering and moving DNA in bacteria cells.

A*STAR researchers uncover how bacteria and the immune system generate alarm behavior in fish.

A*STAR researchers have turned a bacterial protein into a biosensor that can be used to visualize interactions between proteins.

A*STAR scientists have found a way to boost the activity of neutrophils, a subset of immune cells, against disease-causing fungi.

From replacing the insulin producing cells of the body, to serving as genetic and drug screening platforms, stem cells could change the landscape of available treatments for diabetes.

Targeted mutagenesis is being used to create live-attenuated vaccines against the chikungunya virus.

Estimation plots provide researchers with a more complete picture of the significance of their results than traditional P values, say A*STAR scientists.

By interfering with the production and downstream activity of a molecule called Agrin in tumors, scientists can stop the sprouting of blood vessels that promote cancer progression.